OREANDA-NEWS. December 12, 2012. According to the results of the first nine months of 2012 total sales of the top five best selling prescription medications amounted to RUR 872.0 million, which corresponds to 30.9% of sales in the prescription medications segment and 21.0% of the Company’s total sales.

According to the results of the first nine months of 2012 the top five best selling prescription medications are:

Geptor (Ademetionine; ATC "Digestive tract and metabolism"); sales in the prescription medications segment made 10.2%;

Vero-epoetin (Epoetin beta, ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 6.5%;

Irunine (Itraconazole; ATC "Antimicrobials for systematic use"); sales in the segment made 4.9%;

Doxorubicin (Doxorubicin, ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 4.7%;

Carboplatin-LANS (Carboplatin; ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 4.6%

OTC drugs

The OTC drugs segment is characterized by the high degree of consolidation. It means that the top five best selling medicines make 98.6% of sales.

Xilen (Xylometazoline; ATC "Medications for the treatment of respiratory system"); sales increased by 23.8% as compared to the same period of previous year; sales in the OTC drugs segment made 63.5%;

Slabilen (Sodium picosulfate; ATC "Alimentary tract and metabolism"); 19.2% of sales in the OTC drugs segment;

Motilak (Domperidone; ATC "Alimentary tract and metabolism"); sales in the OTC drugs segment made 11.1%;

Vitasharm and Vitatress (ATC "Vitamins"); sales in the OTC drugs segment made 3.6%;

Ginecotex (Benzalknium chloride; ATC "Medications for the treatment of urogenital organs"); sales increased by 13.4% as compared to the same period of previous year; sales in the OTC drugs segment made 1.2%.

Traditional drugs segment

According to the results of the first nine months of 2012 the top five best selling traditional drugs are:

Vero-Dexamethasone (Dexamethasone; ATC "Hormonal drugs for systematic use"); 42.7% of sales in the traditional drugs segment;

Fluconazole (Fluconazole; ATC "Antimicrobials for systematic use"); 14.3% of sales in the traditional drugs segment;

Vero-Loperamide (Loperamide; ATC "Alimentary tract and metabolism"); 7.9% of sales in the traditional drugs segment;

Pyridoxine (Pyridoxine; ATC "Alimentary tract and metabolism"); 16.6% of sales in the traditional drugs segment;

Vero-ciprofloxacin (Ciprofloxacin, "Antimicrobials for systematic use"); 11.6% of sales in the traditional drugs segment.

Non-pharamaceutical products

According to the results of the first nine months of 2012 the top five best selling non-pharamaceutical products are:

Conventional antimicrobial adhesive bandages; 48.7% of sales in the segment;

Conventional reel adhesive bandages; 22.4% of sales in the segment;

Therapeutic plasters - pepper plasters; 11.3% of sales in the segment;

Therapeutic plasters - corn plasters; 15.8% of sales in the segment;

Cosmetic products (Veromistin Silver, Daily, Flores); 0.9% of sales in the segment.

NEW DRUGS PRODUCTION AND SALES

During the first nine months of 2012 Veropharm started production and sales of the new forms and dosages of the drugs:

Poludan (Polyadenilic acid + Polyuridilic acid; ATC "Medications for the sense organs treatment"); new dosage – nasal drops 50 IU/ml 5 ml №1;

Aprotex (Aprotinin, ATC "Medications affecting hematogenesis and blood"); new dosages - 10000 KIU/ml 10 ml №1, 10000 KIU/ml 50 ml № 1 and 10000 KIU/ml 10 ml № 25;

Bergolak (Cabergoline; ATC "Medications for the urinogenital organs treatment"); new dosage – tabl. 0.5 mg №2;

Mielastra (Filgrastim; ATC "Antineoplastic and immunomodulating agents"); new dosages – 30 mln IU/ml 1.6 ml №1 and 30 mln IU/ml 1 ml №5;

Vero-Netilmicin (Netilmicin; ATC "Antimicrobials for systematic use"); new dosage – solution for injection 25mg/ml 2 ml №1;

Tautax (Docetaxel; ATC "Antineoplastic and immunomodulating agents"); new dosage – 20 mg/ml 2 ml №1;

Cerepro (Choline alfoscerate; ATC "Medications for the treatment of central nervous system deseases"); new dosage – 250 mg/ml 4 ml №5;

Rubida (Idarubicin, "Antineoplastic and immunomodulating agents"); new dosage – 1 mg/ml 10 ml №1;

Torin (Sertraline; ATC "Medications for the treatment of central nervous system deseases"); new dosage – tabl. 0.05g №28.

NEW DRUGS REGISTRATION

During the first nine months of 2012 Veropharm received registration for the following drugs:

Topotecan (Topotecan, ATC "Antineoplastic and immunomodulating agents"); new dosage – liophilizate for infusion solution 1 mg;

Veromistin Silver (Benzyldimethyl-myristoikamino-propylammonium monohydrate, ATC “Medications for dermatopathy treatment”); new form - napkins for intimate hygiene;

Veromistin Daily (Benzyldimethyl-myristoikamino-propylammonium monohydrate, ATC “Medications for dermatopathy treatment”); new form – cleaning wet towels.

Additionally, 14 more drugs are currently at different stages of the registration process.